Original Article

*In vitro* study of the effect of a probiotic bacterium *Lactobacillus rhamnosus* against herpes simplex virus type 1

Soghra Khani\(^a\), Mohammad Motamedifar\(^a\)*, Hossein Golmoghaddam\(^b\), Hamideh Mahmoodzadeh Hosseini\(^c\), Zahra Hashemizadeh\(^a\)

\(^a\)Department of Bacteriology and Virology, Shiraz HIV/AIDS Research Center (SHARC), Shiraz University of Medical Sciences, Shiraz, Iran
\(^b\)Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran
\(^c\)School of Pharmacy, Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

**ARTICLE INFO**

**Article history:**
Received 15 August 2011
Accepted 17 November 2011

**Keywords:**
Probiotic
*Lactobacillus rhamnosus*
Herpes simplex virus type 1

**ABSTRACT**

**Background:** Due to the emergence of drug resistance in herpes simplex virus type 1 (HSV-1), researchers are trying to find other methods for treating herpes simplex virus type 1 infections. Probiotic bacteria are effective in macrophage activation and may have antiviral activities.

**Objective:** This study aimed at verifying the direct effect of *Lactobacillus rhamnosus*, a probiotic bacterium, in comparison with *Escherichia coli*, a non-probiotic one, on HSV-1 infection, and determining its effect on macrophage activation for *in vitro* elimination of HSV-1 infection.

**Methods:** The above bacteria were introduced into HSV-1 infected Vero cells, and their effects were examined using both MTT and plaque assay. To determine macrophage activation against *in vitro* HSV-1 infection, J774 cells were exposed to these bacteria; then, macrophage viability was examined with the MTT method, and tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ), and nitric oxide (NO) assessments were performed using the ELISA method.

**Results:** A significant increased viability of macrophages was observed (p < 0.05) in the presence of *Lactobacillus rhamnosus* before and after HSV-1 infection when compared with *Escherichia coli* as a non-probiotic bacterium. However, tumor necrosis factor α concentration produced by *Escherichia coli*-treated J774 cells was significantly higher than *Lactobacillus rhamnosus*-treated J774 cells (p < 0.05). Interferon-gamma and NO production were not different in the groups treated with *Escherichia coli* or with *Lactobacillus rhamnosus*.

**Conclusion:** The results of this study indicate that *Lactobacillus rhamnosus* enhances macrophage viability for HSV-1 elimination and activation against HSV-1 more effectively, when compared with non-probiotic *Escherichia coli*. It also seems that receptor occupation of macrophage sites decreases HSV-1 infectivity by both of the studied bacteria.
Introduction

Herpes simplex virus-1 (HSV-1) can cause two types of infection. The initial infection, most often asymptomatic, involves the epithelial cells and can be latent in the sensory nerve ganglia. In a few infected individuals, the latent viruses are activated under different stress conditions, for instance sunshine, hormonal changes, fever, appearing as cold sore. HSV-1 is the agent of many diseases such as gingivostomatitis, sore throat (pharyngitis), herpetic whitlow, keratoconjunctivitis, herpes encephalitis and meningitis. In immunosuppressed patients, it can be a chronic destructive process. 1-3 Both specific and non-specific defense mechanisms against HSV-1 are important. Host genetic background, macrophages, NK cells, and T-cells and antibodies are important factors in the defense against HSV-1. 1,2 Macrophage activation can also reduce infection by the virus. 4 Anti-viral drugs including acyclovir, vidarabine, famciclovir, valacyclovir, penciclovir are widely used in the treatment of HSV-1 infection. 1,2 Nowadays, the occurrence of mutations in viral DNA polymerase and thymidine kinase has led to an increase in drug resistance to nucleoside analogs such as acyclovir. 4,5 To find appropriate alternatives, researchers suggest seeking new chemical and plant sources of therapy for HSV-1 infections. 6-10

Considering the role of specific and non-specific host defenses against HSV-1, some therapies can work to strengthen and activate the innate and specific immune system components against HSV-1. 11 Coordinating operations of macrophages in anti-herpetic response occur during the first hour of virus invasion. The first defensive line is production and secretion of cytokines such as type I interferon (IFN) and tumor necrosis factor (TNF). Subsequently, IL-12 and IFN-γ are produced, thereby resulting in natural killer cell and macrophage activation. The production of active oxygen radicals (ROS) and of NO are auxiliary mechanisms to improve anti-viral response. 12-15 Macrophages have receptors for molecules such as lipopolysaccharide, mannose, and unmethylated CPG repeats of bacteria. 16 Signals resulting from the combination of these factors increase the secretion of a wide range of cytokines, which strengthen the innate immune system and activate the specific immune system, especially T cells, against pathogens such as viruses. 17,18 Among them, INF-γ launches various activities in macrophages, including antimicrobial activity, causing eradication of intracellular pathogens. Macrophage activity is one of the first steps in preventing virus proliferation (HSV, HSV, VZV) in infected cells. Also, antigen processing and activity is one of the first steps in preventing virus proliferation causing eradication of intracellular pathogens. Macrophage activities in macrophages, including antimicrobial activity, such as lipopolysaccharide, mannose, and unmethylated CPG repeats of bacteria. 16 Signals resulting from the combination of these factors increase the secretion of a wide range of cytokines, which strengthen the innate immune system and activate the specific immune system, especially T cells, against pathogens such as viruses. 17,18 Among them, INF-γ launches various activities in macrophages, including antimicrobial activity, causing eradication of intracellular pathogens. Macrophage activity is one of the first steps in preventing virus proliferation (HSV, HSV, VZV) in infected cells. Also, antigen processing and presentation to Th1 lymphocytes by macrophages induce cell-mediated immunity. 15-18 NO induction of the macrophages in an inflammatory response is also an innate immune defense system. 19 NO has different tasks such as killing infected cells, tumor cells, and parasitic pathogens. Antiviral effect of NO in various viral infections has also been documented. 20

Probiotic bacteria such as Lactobacillus and Bifidobacterium, which typically ferment dairy foods in human and animal digestive tracts, can balance the immune system and increase the specific and non-specific immune responses. They are important as immunomodulatory bacteria in the body’s defense against pathogens such as viruses (HIV, VZV). 21,22 Various studies have shown that Lactobacillus rhamnosus (strain GG), a species of probiotic bacteria, has beneficial effects in treating Rotavirus gastroenteritis in infants. 23,24 Several studies from in vitro systems, animal models, and humans, suggests that probiotics can enhance both specific and nonspecific immune responses. 25,26

In a study, it was demonstrated that consumption of lactic acid bacteria in guinea pigs has anti-influenza effects. Also, taking 1 x 10⁶ cfu/mL of lactic acid bacteria decreases genital herpes complications caused by HSV-2. 27 In another study, the effect of probiotic bacteria for prevention and treatment of viral diarrhea caused by rotavirus, astrovirus, calicivirus, enteric adenovirus and coronavirus was reviewed, and the helpful role of probiotic bacteria in limiting viral diarrhea was documented. 26 In an in vitro study, it was demonstrated that probiotic bacteria increase the antiviral response against vesicular stomatitis virus (VSV) by activating macrophages. 31

So, the emergence of antiviral drug resistance observed in HSV-1 makes it necessary to find other alternatives for treating HSV-1 infection. Considering the important role of macrophages in eliminating viral infections and the effective role of probiotic bacteria in the removal of viral infections (including HSV), this study aimed to investigate: 1) the direct effect of Lactobacillus rhamnosus, a probiotic bacterium, on HSV-1; and 2) its effect on macrophage activation for in vitro elimination of HSV-1 infection. In this way, the possible use of probiotics to inhibit HSV-1 infection would be scientifically proven as an alternative treatment.

Methods

Bacteria and cytotoxic assays

Lyophilized standard strains of Lactobacillus rhamnosus (PTCC 1637) and E. coli (PTCC 25923) were provided by the Iranian Research Organization for Science and Technology, Tehran, Iran. Lactobacilli rhamnosus was cultured to log phase growth in L-cystein HCL supplemented by Man Rogosa Sharp (MRS) broth (Himedia – India) under anaerobic conditions at 37°C, overnight. In order to isolate single bacterial colonies, the harvested broth was transferred to MRS agar (Himedia – India) and incubated under the described conditions for 24-36 hours.

The maximum number of bacteria introduced into the antiviral assays was determined as the highest number of bacteria that was not cytotoxic to the macrophage cell line J774 (data not shown). The value was determined to be 1 x 10⁶ CFU/mL of each strain.

To prepare 1 x 10⁶ CFU/mL of viable bacteria for stimulation experiments, isolated colonies were suspended in PBS. The optical density (OD) was measured by spectrophotometer at 530 nm. Colony concentration was determined via internal McFarland standard OD comparison.

The percentage of adherent bacteria was determined by co-incubation of bacteria with the macrophage cell line for 90 minutes, at 37°C, in a humidified atmosphere of 5% CO₂. Non-adherent bacteria were removed from the cell cultures by washing twice with PBS. The cells were harvested and the percentage of adherent bacteria was determined by agar plate counts of serially diluted suspensions plated on MRS agar. In
order to prepare inactivated bacterial suspension, the culture was frozen at 1 × 10^8 CFU/mL count and thawed in boiling water for 3 cycles. Also, E. coli was grown to log phase growth in EMB agar (Merck – Germany) at 37°C overnight.11

**Virus**

HSV-1 was isolated from the lip lesions of a patient and was confirmed by neutralization test using guinea pig anti-HSV-1 serum (NIH – USA) and monoclonal anti-HSV-1 antibodies against HSV glycoproteins D and G.28

HSV-1 was grown to a titer of 10^8/mL in Vero cell line, in the maintenance medium of Dulbecco modified Eagles growth medium (DMEM, Sigma) supplemented with 2% fetal bovine serum (Gibco – Germany), 0.14% (v/v) sodium bicarbonate, 100 U/mL penicillin, 100 μg/mL streptomycin sulphate, and 0.25 μg/mL amphotericin B. The virus was stored at −70°C until used. For the antiviral assay, 100 μL of the virus with a plaque-forming unit of 50% per mL was used.

**Cells**

The murine monocyte/macrophage cell line J774 cells were obtained from the Pasteur Institute, Tehran, Iran. They were grown until confluence in RPMI 1640 media (Gibco – Australasia) containing 10% fetal bovine serum (FBS), and supplemented with 100 μg/mL streptomycin and 100 IU/mL penicillin in tissue culture flasks (Nunc – Denmark), at 37°C, in an atmosphere of 5% CO₂.

Also, confluent Vero African green monkey kidney cells (Razi Institute, Hesarak – Iran) were prepared in DMEM, supplemented with 8% fetal calf serum. For Vero cells maintenance, DMEM medium was used supplemented with only 2% fetal calf serum. In order to evaluate cell viability, the trypan blue dye (Merck – Germany) exclusion method was performed.29

**Plaque assays**

Possible inhibitory effect of the studied bacteria on HSV-1 was investigated using plaque reduction assay, as previously described.10 Phosphate buffered saline (PBS)-washed confluent Vero cells in 24-well plates (Nunc – Denmark) were treated with the maintenance medium containing plates (Nunc – Denmark). They were treated first with the maintenance medium, containing 1 × 10^6 CFU/mL of live or bacterial debris suspension of E. coli and L. rhamnosus, for 90 min, and then with 50 PFU/100 μL HSV-1, for 40 min. In another series of the experiments under the described conditions, the cells were first exposed to the virus and then to the bacteria; they were also simultaneously exposed to the bacteria and virus. After removing these treatments, the monolayers were overlaid with 1% carboxymethyl cellulose (CMC) in the maintenance medium, and were incubated at 37°C with 5% CO₂ for four days. Controls for each series of the experiment included uninfected cell monolayers, and virus-infected treated or untreated cells with the bacteria. The virus plaques formed on the cells were fixed with methanol for 10 min, and stained with 0.5% crystal violet solution.28

**MTT assay**

The MTT assay (3-4, 5 dimethyl thiazol- 2 yl)-2, 5- diphenyl tetrazolium bromide) (Sigma – USA) was used to assess the living cells according to measured active mitochondrial metabolic function. The assay was able to indicate potential beneficial effects of antiviral agents.29 Briefly, after the incubation period (24 hours at 37°C in presence of 5% CO₂) on a 96-well plate containing 90 μL of serial dilution of cell suspension with the cell concentration of 1 × 10^5, 5 × 10^4, 2.5 × 10^4, 1.25 × 10^4, 6,250 cell/mL, the wells were washed. Then, 10μL of ready MTT dye was added. The plate was incubated at 37°C for 4-3 hours. After this period, the contents were centrifuged for 10 min at 300 rpm, the supernatant was removed, and the cells were suspended in 100 μL DMSO. The optical density of each well was determined at 570 nm, using an ELISA reader.30

**Assays of the effect of J774 cell culture supernatant treated with L. rhamnosus on HSV-1 infected Vero cell**

1 × 10^5 cell/mL of J774 cells were incubated in a 24-wells plate, at 37°C, in the presence of 5% CO₂ for 24 hours; 1 × 10^3 CFU/mL living and/or bacterial debris suspension was added to a separate well plate. Prior to the PBS washing, the cells were remained at 37°C for 90 min to adhere the bacteria to the cells. The plate was incubated at 37°C in the presence of 5% CO₂ for another 48 hours until NO and other cytokines were released. In the next stage, 90 μL of the supernatant of J774 cells treated with bacteria were transferred to the plate containing 50 PFU/100 μL HSV-1 infected Vero cells. After 45 min, the percentage of viable cells was measured using the MTT test, as described above. The wells containing non-infected Vero cells and free supernatant of J774 cells treated with bacteria were considered as controls.

**Assays of the effect of L. rhamnosus on J774 cell line activation against HSV-1**

24-hour-incubated plates of 1 × 10^5 cell/mL of J774 cells were inoculated with 1 × 10^6 CFU/mL living and/or bacterial debris suspension for 90 min, and then infected with 50 PFU/100 HSV-1 for 40 min.

In another series of experiments, the cells were infected with 50 PFU/100 μL HSV-1 for 40 min, and then inoculated with 1 × 10^8 CFU/mL living and/or bacterial debris suspension for 90 min. The plates were incubated at 37°C in the presence of 5% CO₂ for 24 hours. The percentage of metabolically active cells was determined via MTT test, as described. The well containing neither virus nor bacterium was considered as the negative control. Prior to performing the MTT test, the supernatant of all the cells was collected to measure NO, INFγ, and TNFα levels.

**NO measurement**

To measure NO concentration, levels of released NO were measured using the Griess reaction.31 100 μL of supernatant from incubated 1 × 10^8 cell/mL of J774 cells only, J774 cells treated with L. rhamnosus, inactivated L. rhamnosus, E.coli
and inactivated E. coli, at 37°C in the presence of 5% CO₂ for 48 hours, were added to the ELISA plate separately, with 100 μL of modified Griess reagent (Merck – Germany). After 10 min incubation at room temperature, the absorbance at 450 nm was measured. The concentration of NO was calculated using NaN3 standard curve.

**INFγ and TNFα levels determination**

INFγ and TNFα levels were detected using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Bender Medsystem – USA) according to the manufacturer’s instructions. 100 μL of supernatant from incubated 1×10⁸ cell/mL of J774 cells only, J774 cells treated with L. rhamnosus, inactivated L. rhamnosus, E. coli and inactivated E. coli at 37°C in the presence of 5% CO₂ for 48 hours were added to the ELISA plate separately.

**Statistical analysis**

All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 11.5 software (Chicago, IL, USA). The difference between the two groups (L. rhamnosus and E. coli) was tested using the Mann-Whitney test. The J774 cells only were used as a control. P-values less than or equal to 0.05 were considered as statistically significant.

**Results**

**L. rhamnosus significantly enhanced HSV-1 infected Vero cells viability**

Compared to HSV-1 infected control cells, L. rhamnosus significantly increased cell viability of the HSV-1 infected Vero cells either pre or post HSV-1 infection [(49 ± 1.1%, 47.6 ± 1.5%, respectively) (41.7 ± 1.1%) (p ≤ 0.05)]. E. coli showed a similar effect on the elevation of Vero cells viability (Fig. 1).

**Supernatant of treated macrophage J774 culture with L. rhamnosus and E. coli significantly increased Vero cell viability**

As shown in Fig. 2, the supernatant of pre-treated macrophage J774 cells with live and/or inactive L. rhamnosus significantly increased the Vero cell viability in comparison to cells infected with the virus only (74.9 ± 0.95 – 51 ± 2.9) (p ≤ 0.05). However, E. coli treatment caused a lower Vero cell viability, but the difference was not significant (p ≥ 0.05).

| Table 1 - Comparison of number of plaques of Vero cells infected with HSV-1 in different experiments |
|---------------------------------------------------------------|
| **Experiment conditions** | **Mean numbers of plaques ± SD** |
| Vero cell monolayer | 0 |
| Vero + HSV-1 | 83.3 ± 2.08 |
| Vero + HSV-1 + L. rhamnosus | 71 ± 2.0 |
| Vero + HSV-1 + E. coli | 73 ± 3.0 |
| Vero + L. rhamnosus | 0 |
| Vero + E. coli | 0 |
| Vero + L. rhamnosus + HSV-1 | 68 ± 1.0 |
| Vero + E. coli + HSV-1 | 69 ± 0.57 |

**Fig. 1 - Comparison of Vero cells viability percentages under different conditions using the MTT test.**

**Fig. 2 - Comparison of cell viability percentages of HSV-1 infected Vero cells affected by J774 culture supernatant treated with L. rhamnosus and E. coli suspensions.**

A, Vero cells; B, Vero cells+HSV-1; C, Vero cells+HSV-1+ J774 supernatant treated with live L. rhamnosus; D, Vero cells+HSV-1+ J774 supernatant treated with live E. coli; E, Vero cells+HSV-1+ J774 supernatant treated with inactive L. rhamnosus; F, Vero cells+HSV-1+ J774 supernatant treated with inactive E. coli; G, Vero cells+ J774 supernatant.
L. rhamnosus caused increased viability of macrophage J774 cells infected with HSV-1

As shown in Fig. 3, a significantly increased viability of J774 cells was observed after L. rhamnosus treatment of J774 cells pre and post-infection with HSV-1 versus non-treated J774 cells and E. coli-treated J774 cells (p ≤ 0.05).

Pro-inflammatory cytokines and NO production were stimulated in the presence of bacteria

Co-incubation of J774 cells with suspension of either live or inactive L. rhamnosus or E. coli stimulated macrophages to produce NO, TNF-α and IFN-γ (Table 2). E. coli caused significantly higher TNF-α production compared to L. rhamnosus (p = 0.019). A remarkable induction of TNF-α production was observed by J774 cells exposed to live E. coli suspension pre and post infection with HSV-1, as well as to inactive E. coli (p = 0.027). Such effect was not seen with L. rhamnosus. Live or inactive suspensions of L. rhamnosus or E. coli did not stimulate NO or IFN-γ secretion in HSV-1 infected J774 cells.

Discussion

Clinical interventional studies have identified those specific probiotics that have antiviral effects via shortening of the infectious period or decreasing the risk of certain viral infection. The best finding was the beneficial influence of probiotics on viral diarrhea in infants and children.32

In a study on anti HSV-2 effect of selected vaginal Lactobacillus strains (L. brevis CD2, L. salivarius FV2, L. plantarum FV9), Conti et al. demonstrated the inhibitory effect of living bacterial cells on HSV-2, through several mechanisms, including interference with early steps of virus replication such as binding/entry, and the production of lactic acid and hydrogen peroxide, with a direct antiviral effect.33

There are also two separate reports demonstrating the protective effects of various lactic acid bacteria on VSV-infected porcine epithelial and macrophage cell lines.34,11

With regard to the proven antiviral effect of probiotic strains and to researchers’ attempts to create an appropriate protocol to treat or prevent HSV-1 infection, we decided to test a probiotic bacterium as a candidate for such a purpose. In this study we evaluated the in vitro effects of L. rhamnosus, a probiotic bacterium, directly on HSV-1 infections, and its influence on stimulation of NO release and TNF-α and IFN-γ production as pro-inflammatory cytokines following L. rhamnosus activation of murine monocyte/macrophage J774 cell line.

Our results clearly demonstrated that L. rhamnosus exposure enhanced the viability of J774 cell line up to 90%, which is remarkable in comparison to the results reported by Ivec et

Table 2 - The levels of TNF-α, NO and IFN-γ measured by ELISA in different conditions on this study

| Experiment conditions | NO (µg/mL) Mean ± SD | IFN-γ (pg/mL) Mean ± SD | TNF-α (pg/mL) Mean ± SD |
|-----------------------|----------------------|------------------------|------------------------|
| J774                  | 0                    | 7.1 ± 0.57             | 17.3 ± 2.08            |
| J774 + HSV-1          | 0.11 ± 0.015         | 14.5 ± 0.73            | 286 ± 4.6              |
| J774 + L. rhamnosus   | 0.14 ± 0.01          | 14.1 ± 1.52            | 205 ± 2.88             |
| J774 + E. coli        | 0.12 ± 0.02          | 16.1 ± 1.52            | 452 ± 2.51             |
| J774 + L. rhamnosus + HSV-1 | 0.13 ± 0.01      | 16.6 ± 1.52            | 236 ± 2.51             |
| J774 + HSV-1 + L. rhamnosus | 0.11 ± 0.01  | 16 ± 1.15              | 276 ± 2.3              |
| J744 + E. coli + HSV-1| 0.11 ± 0.01         | 14.1 ± 1.52            | 323 ± 3.0              |
| J774 + HSV-1 + E. coli| 0.12 ± 0.01         | 15.1 ± 1.52            | 372 ± 3.0              |
| J774 + inactive L. rhamnosus + HSV-1 | 0.11 ± 0.01  | 13.1 ± 1.52            | 227 ± 2.64             |
| J774 + inactive E. coli + HSV-1 | 0.11 ± 0.01 | 13 ± 1.0               | 368 ± 3.05             |
al. (30% viability of VSV infected 3D4/21 cell line). The cause of viability increase can be due to difference of cell line, VSV infectious capacity versus HSV-1, or probiotic species between the two studies. Also, we detected more protective effect of live bacteria than inactive bacteria on the exposure of viral infected macrophages, a finding consistent with Ivec et al.’s report. A mechanism involved in the protective effect of probiotic bacteria against virus particles is competition for cell surface attachment. This has already been proven in vitro, and reported as a feasible mechanism for the protection of cells in the case of VSV infection.6,11

Preservation of a CpG motif in bacterial DNA during inactivation of bacteria has been reported to suppress the apoptotic pathways and enhance the cell viability.11,15 Our study demonstrated the higher viability of HSV-1 infected macrophage J774 cells treated with L. rhamnosus when compared to E. coli treatment, although the reason is unclear. One explanation of lower cell viability in the case of E. coli exposure compared to L. rhamnosus can be related to increased TNF-α production induced by E. coli, which causes more cell apoptosis. We showed more TNF-α production induced by E. coli exposure pre- and post-HSV-1 infection of the cells compared to L. rhamnosus. The presence of lipopolysaccharide in the cell wall of E. coli is a potential stimulator for TNF release.36

Increased viability of infected Vero cells by a supernatant of J774 cells exposed to L. rhamnosus might result from NO, TNF-α and IFN-γ production, as pro-inflammatory cytokines.11,15 This suppressed HSV-1 proliferation. NO release is another antiviral mechanism, which has also been previously reported. In fact, significant increase of NO release was reported in co-incubated macrophage exposed to probiotic bacteria in the presence of IFN-γ, however, Ivec et al. stated that IFN-γ is not an important factor in the stimulation of NO release.11,17

In our study, J774 cells co-incubated with live or inactive L. rhamnosus or E. coli were capable of inducing TNF-α, IFN-γ and NO production. Concentration of IFN-γ and its dependent mediator, NO, is lower than those of a previous report. However, in that report, probiotic bacteria were applied with exogenous IFN-γ, so it can be concluded that the simultaneous presence of IFN-γ with probiotic bacteria might be necessary for the production of high levels of NO.37 In the case of inactive bacteria, cell wall components such as peptidoglycan, lipoteichoic acid and CpG motifs can induce NO, TNF-α and IFN-γ production by cells; however, their levels were lower than those induced by live bacterial exposure.11

In conclusion, L. rhamnosus was able to induce several antiviral effects against HSV-1, which might be through different mechanisms including competing with virus for cell surface attachment, increasing macrophage viability, following stimulation of pro-inflammatory responses. Thus, our results suggest future in vivo evaluation of L. rhamnosus for increasing the immune defense in the cells as a probable candidate for HSV-1 infection co-therapy.

Acknowledgements

This article is taken from the MSc thesis of Soghra Khani for Medical Microbiology and was financially supported by Shiraz University of Medical Sciences Grant No. 4008. We also wish to thank Mr. Pedram Taleazadeh Shirazi for his technical assistance.

Conflict of interest

All authors declare to have no conflict of interest.

References

1. Geo FB, Carroll KC, Butel JS, Morse SA. Herpesviruses. In: Jawetz, Melnick and Adelberg’s. Medical Microbiology. 24th ed. McGraw-Hill Companies USA; 2007. p. 428-37.
2. Kapikian A, Hoshino Y, Chanock R. Rotaviruses. In: Knipe D, Howley P, editors. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2479-2601.
3. Whitley RJ. Herpes simplex virus infection. Semin Pediatr Infect Dis. 2002;13(1):6-11.
4. Biswas S, Tiley LS, Zimmerman H, et al. Mutations close to functional motif IV in HSV-1 ULS helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res. 2008;80(1):81-5.
5. Frobert E, Thouvenot D, Lina B, et al. Genotyping diagnosis of acyclovir resistant herpes simplex virus. J Pathol Biol. 2007;55(10):504-11.
6. Pietka-Óttlik M, Wójcieszuk-Młochowska H, Kołodziejczyk K, et al. New organoselenium compounds active against pathogenic bacteria, fungi and viruses. Chem Pharm Bull. 2008;56(10):1423-27.
7. Wang H, Vincent Ooi E, Ang OJ Fr PO. Antiviral activities of extracts from Hong Kong seaweeds. J Zhejiang Univ Sci B. 2008;9(12):969-76.
8. Kratz JM, Andrigbetti-Fröhner CR, Kolling DJ, et al. Anti-HSV-1 and anti-HIV-1 activity of gallic acid and pentyl gallate. Mem Inst Oswaldo Cruz. 2008;103(5):437-42.
9. Rajhbandari M, Mentel R, Jha PK, et al. Antiviral activity of some plants used in nepalese traditional medicine. Evid Based Complement Alternat Med. 2009;6(4):517-22.
10. Koch C, Reichling J, Kehm R, et al. Efficacy of anise oil, dwarf-pine oil and chamomile oil against thymidine-kinase-positive and thymidine-kinase-negative herpesviruses. J Pharm Pharmacol. 2008;60(11):1545-50.
11. Ivec M, Botic T, Koren S, et al. Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus. Antiviral Res. 2007;75(3):266-74.
12. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-46.
13. Denis M. Human monocytes/macrophages: NO or no NO? J Leukoc Biol. 1994;55(5):882-8.
14. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-509.
15. Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus. Virol J. 2005;2:59-89
16. Miettinen M, Lehtonen A, Julkunen I, Mattikainen S. Lactobacilli and Streptococci Activate NF-kB and STAT Signaling Pathways in Human Macrophages. J Immunol. 2000;164(7):3733-40.
28. Motamedifar M, Nekooeian AA, Moatari A. The effect of hydroalcoholic extract of olive leaves against herpes simplex virus type 1. Iran J Med Sci. 2007;32:222-6.
29. Leary JJ, Wittrock R, Sarisky RT, et al. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob Agents Chemother. 2002;46(3):762-8.
30. Bergamini A, Perno CF, Capozzi M, et al. Tetrazolium-based colorimetric assay for quantification of HIV-1-induced cytopathogenicity in monocyte-macrophages exposed to macrophage-colony-stimulating factor. J Virol Methods. 1992;40(3):275–86.
31. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982;126(1):131-8.
32. Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001;33(suppl 2):17-25.
33. Conti C, Malacini C, Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal Lactobacilli. J Physiol Pharmacol. 2009;60(suppl 6):19-26.
34. Botić T, Klingberg TD, Weingartl H, et al. A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteria. Int J Food Microbiol. 2007;115(2):227-34.
35. Jozsef L, Khreiss T, Filep JG. CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes. FASEB J. 2004;18(14):1776–8.
36. Abbas AK, Lichtman AH, Pillai S. Cellular And Molecular Immunology. Elsevier, Philadelphia,.6th ed. 2007.